EDESA BIOTECH INC
EDSANASDAQ🏆 #3368 by market capEarnings Dec 10 · PostUS Equity
$351.67▼ $21.70 (−6.17%)
Simulated price1h—
24h▼ 6.2%
7d—
14d—
30d—
1y—
🏦Market Cap
$53M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
94.7%
High
💵FCF Margin
—
⚖️P/S Ratio
160.0x
Expensive
Otter Score
45
Weak
No chart data available for EDSA.
Trading Snapshot
- Day Range
- $346.40 – $358.37
- 52-Week Range
- $0.72 – $20.32
- Volume
- $3.61B
- Avg Volume
- $4.01B
- Shares Outstanding
- 9.6M
- Next Earnings
- Oct 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $332,413
- Last Q Revenue
- $86,714
- P/E Ratio
- —
- P/S Ratio
- 160.0x
- EPS (TTM)
- $-1.34
- Dividend Yield
- —
Why Investors Own EDSA
- ✓High-growth profile — revenue up +33.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$332,413▲ +26.9% YoY
Gross Margin (TTM)
60.8%▲ +1.4% YoY
Operating Income (TTM)
$57,507▲ +26.9% YoY
Free Cash Flow (TTM)
$30,582▲ +26.9% YoY
About EDESA BIOTECH INC
A company profile for EDESA BIOTECH INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
45/100
Analyst Price Target
ⓘAverage Target
$376.25
▲ +7.0% Upside
High Target$447.14
Low Target$312.03
Based on 20 analysts
Latest News & Updates
🚀
CNBC·2h ago
EDESA BIOTECH INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift EDSA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
EDESA BIOTECH INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.